Nanobac Pharmaceuticals, Incorporated
Nanobac Pharmaceuticals, Incorporated
Your view on NNBP
Overview
What the company does, where it operates, and who runs it.
About Nanobac Pharmaceuticals, Incorporated
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Stanton
- Headquarters
- 3000 Bayport Drive, Tampa, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Stanton
- Headquarters
- 3000 Bayport Drive, Tampa, FL, US
Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs.
The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases.
Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nanobac Pharmaceuticals, Incorporated, and the rating behind it. NNBP last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nanobac Pharmaceuticals, Incorporated. Starting points for Nanobac Pharmaceuticals, Incorporated: beta -35.70 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nanobac Pharmaceuticals, Incorporated. Nanobac Pharmaceuticals, Incorporated does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nanobac Pharmaceuticals, Incorporated. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nanobac Pharmaceuticals, Incorporated. Nanobac Pharmaceuticals, Incorporated has reported as a listed company since 1994. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nanobac Pharmaceuticals, Incorporated valued side by side against its closest peers. Nanobac Pharmaceuticals, Incorporated is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nanobac Pharmaceuticals, Incorporated, and how their positions are changing. At a $24,951 market value, institutional positions materially move Nanobac Pharmaceuticals, Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nanobac Pharmaceuticals, Incorporated executives and directors. Shares of Nanobac Pharmaceuticals, Incorporated have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nanobac Pharmaceuticals, Incorporated. Nanobac Pharmaceuticals, Incorporated is a $24,951 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nanobac Pharmaceuticals, Incorporated. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nanobac Pharmaceuticals, Incorporated. Coverage tracks Nanobac Pharmaceuticals, Incorporated within Biotechnology (Healthcare). Press releases and market coverage, newest first.